Latest news
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data - SahmSahm · Thu, 06 Aug 2026 07:00:00 GMTImcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated - TipRanksTipRanks · Wed, 05 Aug 2026 09:17:30 GMTRYTM: Q2 2026 delivered 19% revenue growth, strong IMCIVREE uptake, and positive RM-718 data - TradingViewTradingView · Tue, 04 Aug 2026 11:53:43 GMTRYTM: IMCIVREE revenue surged 19% sequentially in Q2 2026, driven by strong U.S. demand and clinical progress - TradingViewTradingView · Tue, 04 Aug 2026 11:45:22 GMTImcivree has helped quiet the constant hunger I once lived with - rareobesitynews.comrareobesitynews.com · Fri, 31 Jul 2026 20:58:33 GMTAnalyst Reaffirms Buy on Rhythm as Imcivree Platform Expansion and Next‑Gen MC4R Assets Underpin Overweight Rating and $145 Price Target - TipRanksTipRanks · Mon, 27 Jul 2026 14:25:11 GMT